Orion Corporation (“Orion”) and Marinus Pharmaceuticals, Inc. (“Marinus”) have decided to mutually terminate their European wide marketing and distribution agreement for ganaxolone. Marinus regains ganaxolone’s commercial rights in Europe where the compound is approved for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients two to 17 years of age. CDD is a serious and rare genetic disorder. Orion suspends all

Dec. 23, 2024 -- Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced the acquisition of CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for worldwide (excluding Greater China) development and commercialization, from Vincentage. CX11 is an investigational, oral small molecule GLP-1 RA for t

Dec. 23, 2024 -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADC) and active immunotherapies (4174. TWO), and GlyTech, Inc. (GlyTech), a Japan manufacturer that focuses on glycan production and chemical glycosylation technologies, have entered into a Marketing Agreement and a Material Transfer Agreement. Under the terms of the Marketing Agreement, OBI grants GlyTech rights to market

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health challenge despite the availability of current vaccines This 21-valent pneumococcal conjugate vaccine (PCV21) is the first pneumococcal conjugate vaccine candidate with more than 20 serotypes to enter phase 3 in infants & toddlers December 23, 2024. Sanofi and SK bioscience have entered into a new chapter of

Dec. 23, 2024 -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent License Agreement to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. Tafenoquine is not currently approved by the U.S. Food and Drug Administration (“FDA”) for the treatment and preventio

Acquisition bolsters Eton’s commercial pediatric endocrinology portfolio Product is now available through AnovoRx, a specialty pharmacy dedicated to serving patients with rare and chronic conditions Dec. 20, 2024 -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has completed its previously announced asset purchase of Increlex® (mecasermin inj

Dec. 19, 2024 -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today announces the acquisition of OccuRx, a Melbourne-based biotechnology company with highly complementary assets, resources and expertise, and a shared focus on targeting GPR68, a master switch of fibrosis. The acquisition combines the assets and capabilities of two companies founded by a leader in the GPR68 field, Professor Darren Kelly, consoli

Dec. 19, 2024 -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABO-101, a novel gene editing therapeutic designed to address primary hyperoxaluria type 1 (PH1). The redePHine Phase 1/2 study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficac

Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic target Total potential deal value up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales Dec. 18, 2024 -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaboration and license agre

Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has recently completed an approximately $28 million private financing, which, together with Tvardi’s existing cash and Cara’s anticipated cash balance, is expected to fund the combined company into the second half of 2026 Tvardi anticipates reporting topline data in the second half of 2025 from two Phase 2 clinical programs utili